ClinicalTrials.gg
RecruitingNCT06817265TNTLUpdated Aug 24, 2025

Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy

A Phase 3 interventional study of TNTL and TNTL simulation preparation in Non-Proliferative Diabetic Retinopathy, sponsored by Beletalent (Zhuhai) Pharmaceutical Co., Ltd. Recruiting at 30 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Beletalent (Zhuhai) Pharmaceutical Co., Ltd · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Diabetic Retinopathy with a site in China — 27 open to participants now, 28 under way, 2 of them phase 3. Diabetic Retinopathy · China.

Planned enrollment
11th of 56
360 · median 139
Started
2025
with 8 others
Phase 3
6 of 85
2 open now
Primary completion
2026-08
later than 14 of 27 live
Registered
70th of 85
by date

Among the 85 studies in Diabetic Retinopathy with a site in China, this one is the 11th largest by planned enrollment of the 56 interventional ones that give a count, is one of 9 that started in 2025, is one of 6 in phase 3, reaches primary completion later than 14 of the 27 other live ones, and was the 70th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

27 of the 85 studies in Diabetic Retinopathy with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Diabetic Retinopathy with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug TNTL works to treat non-proliferative diabetic retinopathy in adults. It will also learn about the safety of drug TNTL. The main questions it aims to answer are:

  1. Does drug TNTL can improve visual acuity and reduce the degree of retinopathy?
  2. What medical problems do participants have when taking drug TNTL? Researchers will compare drug TNTL to a placebo (a look-alike substance that contains no drug) to see if drug TNTL works to treat non-proliferative diabetic retinopathy.

Participants will:

  1. Take drug TNTL or a placebo every day for 6 months
  2. Visit the clinic once every 4 weeks for checkups and tests
  3. Keep a diary of their symptoms and Change from baseline
03

Conditions studied

  • Non-Proliferative Diabetic Retinopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age range of 18 to 75 years old (including boundary values);
  • Conform to the diagnosis of type 2 diabetes and diabetes retinopathy. diabetes retinopathy is classified as NPDR and mild and moderate patients;
  • Patients with the best corrected visual acuity (BCVA) of the target eye is ≥ 34 points (ETDRS visual acuity chart, visual acuity equivalent to a score of 20/200, decimal 0.1);
  • Patients who meet the syndrome differentiation criteria of Yin deficiency, internal heat, and eye meridian stasis in traditional Chinese medicine;
  • During the screening period, (HbA1c) should be ≤ 8.5%;
  • Agree to participate in this clinical study and voluntarily sign the form.

Exclusion criteria

Exclusion Criteria:

  • Patients with no light perception in one eye;
  • Patients with macular edema who require anti Vascular Endothelial Growth Factor(VEGF) treatment;
  • People with other eye diseases, such as retinal artery or vein occlusion, non diabetes retinopathy, retinal detachment, uveitis, glaucoma, corneal ulcer, cataract affecting fundus examination, optic neuropathy and high myopia with fundus changes;
  • Patients with acute complications of diabetes (such as diabetes ketoacidosis, hyperglycemia hyperosmolality syndrome, diabetes lactic acidosis, etc.) within one year before the screening period;
  • People with other eye related complications of diabetes, such as iris neovascularization, angle neovascularization, and retinal neovascularization;
  • acupuncture and moxibustion and other external treatment methods of traditional Chinese medicine were used to treat diabetes retinopathy within one week before enrollment;
  • Patients who have used drugs clearly stated in the instruction manual to treat diabetes retinopathy, such as calcium dobesilate, pancreatic kallidinogenase, Qiming Granules, Shuangdan Mingmu Capsules, Compound Danshen Dropping Pills, Tongluo Mingmu Capsules, etc. within 2 weeks before enrollment;
  • Patients who have undergone glaucoma, vitreous, retinal and other intraocular surgeries and procedures in the target eye within 3 months before enrollment;
  • Patients who have undergone cataract surgery in the target eye within 3 months prior to enrollment and have not yet stabilized according to the researcher's assessment;
  • Patients who have received intravitreal injections of anti VEGF antibodies and in the target eye within 3 months prior to enrollment;
  • Patients who have undergone total retinal laser photocoagulation treatment in the target eye;
  • For those whose refractive media is turbid and difficult to evaluate fundus images in the target eye;
  • Uncontrolled or controlled blood pressure with systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg;
  • When screening, (ALT) or aspartate aminotransferase (AST) should be ≥ 1.5 times the value;
  • Patients with serious kidney disease (such as azotemia and uremia), diabetes foot, etc;
  • When screening, individuals with severe primary diseases such as respiratory, cardiovascular, cerebrovascular, endocrine, digestive, and hematopoietic systems, or those with severe mental illnesses should be included;
  • Suspected or confirmed history of alcohol or drug abuse;
  • Pregnant women, lactating women, or women of childbearing age who are preparing to conceive; Female subjects of childbearing age or male subjects (with partners of childbearing age) who do not agree to voluntarily take effective measures within one month after the last dose during the screening period;
  • Individuals who are allergic to the drugs or their components used in this experiment;
  • Participants who have participated in other clinical trials within the past month;
  • The researchers believe that participants should not participate in the clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
360 participants (estimated)

Study arms

  • Active comparator
    TNTL Experimental Group

    TNTL, oral, 4 tablets, 3 times a day, after meals. Take it for 24 weeks.

    Drug: TNTL

  • Placebo comparator
    TNTL Control Group

    TNTL simulation preparation,oral, 4 tablets, 3 times a day, after meals. Take it for 24 weeks.

    Drug: TNTL simulation preparation

Interventions

  • DrugTNTL

    oral, 4 tablets, 3 times a day, after meals. Take it for 24 weeks.

  • DrugTNTL simulation preparation

    oral, 4 tablets, 3 times a day, after meals. Take it for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Change in best corrected visual acuity (BCVA) from baseline after 24 weeks of medication;

    After 24 weeks of medication, the subjects' best corrected visual acuity (BCVA) was checked and compared with the value measured at week 0 to observe the degree of change from baseline value;

    Time frame: From enrollment to the end of treatment at 24 weeks

Secondary outcomes

  1. Change in best corrected visual acuity (BCVA) from baseline after medication

    After 4 weeks,8weeks,12weeks,16weeks,20weeks of medication, the subjects' best corrected visual acuity (BCVA) was checked separately and compared with the value measured at week 0 to observe the degree of change from baseline value;

    Time frame: From enrollment to the end of treatment at 4 weeks,8weeks,12weeks,16weeks,20weeks

  2. The change and progression rate of ETDRS classification DR Classification from baseline after 12 and 24 weeks of medication;

    After 12 weeks,24 weeks of medication, the subjects' ETDRS classification based on the Diabetic Retinopathy Severity Score and compared with the value measured at week 0 to observe the change and progression rate from baseline value as required, with a minimum score of 10 and a maximum score of 90. The higher the score, the more severe it is.

    Time frame: From enrollment to the end of treatment at 12weeks and 24weeks.

  3. The proportion of subjects whose best corrected visual acuity (BCVA)increased by ≥ 5, ≥ 10, ≥ 15 compared to baseline after medication;

    After 4,8,12,16,20,24 weeks of medication, count the proportion of subjects whose best corrected visual acuity(BCVA) increased by ≥ 5, ≥ 10, ≥ 15 compared to baseline

    Time frame: From enrollment to the end of treatment at 4,8,12,16,20, and 24 weeks

  4. The proportion of subjects whose best corrected visual acuity (BCVA) decreased by ≥ 5, ≥ 10, ≥ 15 compared to baseline after medication

    After 4,8,12,16,20,24 weeks of medication, count the proportion of subjects whose best corrected visual acuity(BCVA) decreased by ≥ 5, ≥ 10, ≥ 15 compared to baseline

    Time frame: From enrollment to the end of treatment at 4,8,12,16,20, and 24 weeks

  5. Changes in fundus condition compared to baseline

    Changes in fundus condition compared to baseline after 12 and 24 weeks of medication

    Time frame: From enrollment to the end of treatment at 12 and 24 weeks.

  6. Changes in retinal macular optical coherence tomography (OCT) compared to baseline

    Changes in retinal macular optical coherence tomography(OCT) after 12 and 24 weeks of medication compared to baseline

    Time frame: From enrollment to the end of treatment at 12 and 24 weeks.

  7. Changes in HemoglobinA1c compared to baseline

    Changes in HemoglobinA1c levels compared to baseline after 12 and 24 weeks of medication

    Time frame: From enrollment to the end of treatment at 12 and 24 weeks.

  8. Changes in fasting blood glucose compared to baseline

    Changes in fasting blood glucose levels after 4, 8, 12, 16, 20, and 24 weeks of medication compared to baseline

    Time frame: From enrollment to the end of treatment at 4,8,12,16,20, and 24 weeks

  9. Effective rate of traditional Chinese medicine syndrome

    After medication, use the Traditional Chinese Medicine Syndrome(yin deficiency with internal heat and blood stasis obstructing the collaterals of the eyes) Scale as required to score and calculate the effective rate,the lowest score is 0, the highest score is 30, and the higher the score, the more severe it is.

    Time frame: From enrollment to the end of treatment at 4,8,12,16,20, and 24 weeks

Other outcomes

  1. Adverse events and reactions

    Record adverse events, including number of participants with abnormal vital signs,urine analysis, urinalysis,liver function , etc

    Time frame: From enrollment to the end of treatment at 24 weeks

07

Study locations

30 of 30 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Aug 2026, 16 months after the start.

Of 21 phase 3 interventional studies under Diabetic Retinopathy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 41. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2025
First posted
Feb 10, 2025
StartActual
Apr 29, 2025
Primary completionEst.
Aug 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06817265
Lead sponsor
Beletalent (Zhuhai) Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Apr 29, 2025
Primary completion
Aug 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 24, 2025

Study contacts

Jinxin Clinical Project Manager
Contact
trade@beletalent.com
+86 13885383954
Hongsheng Bi
principal investigator · Shandong University of Traditional Chinese Medicine Affiliated Eye Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion